A novel transcatheter system designed for transfemoral mitral valve repair—the NeoChord Nexus system—won the CRT Best Innovation Competition, taking place at the CRT 2022 annual meeting (27 February–1 March, Washington DC, USA).
Azeem Latib (Montefiore Medical Center, New York, USA) presented the results of first-in-man experience with the valve, involving a 55-year-old male patient with a history of coronary artery disease, atrial fibrillation (AF) and prostate cancer. The patient presented with severe mitral regurgitation and New York Heart Association (NYHA) class 3 heart failure.
According to Latib, 30 days after the implantation of the device, it was shown to be mimicking the native construction of the papillary muscle and the physiological function of the mitral valve.
The investigational NeoChord NeXuS transcatheter mitral chordal repair device is designed to restore function in patients with severe symptomatic primary mitral regurgitation (MR) due to ruptured native chords and the mitral valve’s inability to close properly.
According to NeoChord, the Nexus transcatheter mitral chordal repair device is unique from other mitral valve repair technologies in maintaining a natural physiologic functionality of the mitral valve. It is deployed through the vein using a transfemoral delivery catheter, navigated transeptally to the diseased native mitral valve. Due to minimal hardware used and the proven leaflet connection, NeoChord Nexus preserves options for patients who may need reintervention in the future.
The first 30-day results following implant of the device were presented during PCR London Valves 2021 (21–23 November, London, UK and virtual).
